Renal Cell Cancer Clinical Trials

A listing of Renal Cell Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 401 clinical trials
Featured trial
HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma

. Researchers want to see if this therapy fights kidney cancer cells. Metastatic renal cell carcinoma (RCC) is an incurable condition. Current therapy for this disease consists of the serial administration

primary cancer
metastatic cancer
clear cell carcinoma
carcinoma
renal cell cancer
  • 210 views
  • 22 Dec, 2020
  • 1 location
Featured trial
AREN03B2: Study of Kidney Tumors in Young Patients

AREN03B2: Study of Kidney Tumors in Young Patients

  • 36 views
  • 08 Nov, 2020
  • 1 location
Featured trial
AREN03B2: Renal Tumors Classification, Biology, and Banking Study

AREN03B2: Renal Tumors Classification, Biology, and Banking Study

  • 106 views
  • 08 Nov, 2020
  • 1 location
Featured trial
A Phase 1/1b Study of Sitravatinib in Combination with Nivolumab and Ipilimumab in Patients with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies

Study 516-008 is an open-label Phase 1 dose escalation/Phase 1b dose expansion study evaluating the safety and tolerability, clinical activity, and PK of sitravatinib in combination with nivolumab and ipilimumab for the treatment of ccRCC and potentially other solid tumor types. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor …

monoclonal antibodies
carcinoma
VEGFR2
nivolumab
tyrosine
  • 57 views
  • 15 Sep, 2020
  • 1 location
Featured trial
A Phase 1b, Dose-escalation Study of Pexa-Vec (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) in Combination With REGN2810 (Anti-PD-1) in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC)

This is a Phase 1b, open-label, multi-center, dose-escalation trial of Pexa-Vec plus REGN2810 in patients with metastatic or unresectable renal cell carcinoma (RCC). The trial consists of a

metastatic renal cell carcinoma
karnofsky performance status
carcinoma
clear cell renal cell carcinoma
systemic therapy
  • 2 views
  • 23 Nov, 2020
  • 3 locations
Featured trial
Procurement of Human Biospecimens for Research

Procurement of Human Biospecimens for Research

  • 53 views
  • 23 Nov, 2020
  • 1 location
Featured trial
Procurement of Human Biospecimens for Research

Procurement of Human Biospecimens for Research

  • 80 views
  • 23 Nov, 2020
  • 1 location
A Phase I/Ib, Open-label, Multi-center Study of DFF332 as a Single Agent and in Combination With Everolimus or IO Agents in Patients With Advanced/Relapsed ccRCC and Other Malignancies With HIF2α Stabilizing Mutations

adenosine A2A receptor antagonist), in patients with advanced clear cell renal cell carcinoma and other malignancies with HIF stabilizing mutations.

everolimus
cancer
carcinoma
vegf
clear cell renal cell carcinoma
  • 16 views
  • 24 Oct, 2022
  • 10 locations